QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
NASDAQ:SUPN

Supernus Pharmaceuticals - SUPN Stock Forecast, Price & News

$41.61
-0.42 (-1.00%)
(As of 02/3/2023 04:29 PM ET)
Add
Compare
Today's Range
$41.04
$42.08
50-Day Range
$35.21
$42.03
52-Week Range
$24.95
$42.09
Volume
547,185 shs
Average Volume
398,038 shs
Market Capitalization
$2.25 billion
P/E Ratio
65.02
Dividend Yield
N/A
Price Target
$47.00

Supernus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
13.9% Upside
$47.00 Price Target
Short Interest
Bearish
10.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.49mentions of Supernus Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.67 M Sold Last Quarter
Proj. Earnings Growth
-58.90%
From $1.63 to $0.67 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

566th out of 1,029 stocks

Pharmaceutical Preparations Industry

279th out of 501 stocks

SUPN stock logo

About Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Stock News Headlines

StockNews.com Lowers Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
SUPN Supernus Pharmaceuticals, Inc.
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Supernus Pharma's Charts Are Looking Super
Supernus Announces Third Quarter 2022 Financial Results
Axsome Therapeutics: All Eyes On Auvelity Launch
Supernus Provides Regulatory Update on SPN-830
Supernus Pharmaceuticals (NASDAQ: SUPN)
Best Momentum Stocks to Buy for August 8th
See More Headlines
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Company Calendar

Last Earnings
11/08/2022
Today
2/03/2023
Next Earnings (Estimated)
4/12/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:SUPN
CUSIP
86845910
Employees
575
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.00
High Stock Price Forecast
$47.00
Low Stock Price Forecast
$47.00
Forecasted Upside/Downside
+13.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$53.42 million
Pretax Margin
4.20%

Debt

Sales & Book Value

Annual Sales
$579.78 million
Cash Flow
$1.97 per share
Book Value
$15.43 per share

Miscellaneous

Free Float
49,739,000
Market Cap
$2.25 billion
Optionable
Optionable
Beta
0.99

Key Executives

  • Jack A. Khattar
    President, CEO, Secretary & Director
  • Timothy C. Dec
    Chief Financial Officer & Senior Vice President
  • Frank Mottola
    Senior VP-Quality, GMP Operations & IT
  • Padmanabh P. Bhatt
    Chief Scientific Officer & Senior Vice President
  • Jonathan Rubin
    Chief Medical Officer & Senior Vice President













SUPN Stock - Frequently Asked Questions

Should I buy or sell Supernus Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SUPN shares.
View SUPN analyst ratings
or view top-rated stocks.

What is Supernus Pharmaceuticals' stock price forecast for 2023?

1 equities research analysts have issued twelve-month price targets for Supernus Pharmaceuticals' stock. Their SUPN share price forecasts range from $47.00 to $47.00. On average, they anticipate the company's share price to reach $47.00 in the next year. This suggests a possible upside of 11.8% from the stock's current price.
View analysts price targets for SUPN
or view top-rated stocks among Wall Street analysts.

How have SUPN shares performed in 2023?

Supernus Pharmaceuticals' stock was trading at $35.67 on January 1st, 2023. Since then, SUPN stock has increased by 17.8% and is now trading at $42.03.
View the best growth stocks for 2023 here
.

When is Supernus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 12th 2023.
View our SUPN earnings forecast
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced its earnings results on Tuesday, November, 8th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.32 by $0.29. The specialty pharmaceutical company had revenue of $177.35 million for the quarter, compared to analysts' expectations of $173.22 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 4.51% and a net margin of 5.72%.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $650.00 million-$680.00 million, compared to the consensus revenue estimate of $674.36 million.

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Stephens Investment Management Group LLC (2.97%), Rice Hall James & Associates LLC (1.15%), Congress Asset Management Co. MA (0.94%), International Biotechnology Trust PLC (0.71%), Tributary Capital Management LLC (0.63%) and Scout Investments Inc. (0.57%). Insiders that own company stock include Frederick M Hudson, Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends
.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $42.03.

How much money does Supernus Pharmaceuticals make?

Supernus Pharmaceuticals (NASDAQ:SUPN) has a market capitalization of $2.27 billion and generates $579.78 million in revenue each year. The specialty pharmaceutical company earns $53.42 million in net income (profit) each year or $0.64 on an earnings per share basis.

How many employees does Supernus Pharmaceuticals have?

The company employs 575 workers across the globe.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The official website for the company is www.supernus.com. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at gpatrick@supernus.com, or via fax at 301-838-2501.

This page (NASDAQ:SUPN) was last updated on 2/3/2023 by MarketBeat.com Staff